...
首页> 外文期刊>Epidemiology and infection >Detection of IgG3 antibodies specific to the human immunodeficiency virus type 1 (HIV-1) p24 protein as marker for recently acquired infection
【24h】

Detection of IgG3 antibodies specific to the human immunodeficiency virus type 1 (HIV-1) p24 protein as marker for recently acquired infection

机译:检测人类免疫缺陷病毒1型(HIV-1)p24蛋白特异的IgG3抗体作为最近感染的标志物

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Reducing the risk of human immunodeficiency virus type 1 (HIV-1) transmission is still a public health priority. The development of effective control strategies relies on the quantification of the effects of prophylactic and therapeutic measures in disease incidence. Although several assays can be used to estimate HIV incidence, these estimates are limited by the poor performance of these assays in distinguishing recent from long-standing infections. To address such limitation, we have developed an assay to titrate p24-specific IgG3 antibodies as a marker of recent infection. The assay is based on a recombinant p24 protein capable to detect total IgG antibodies in sera using a liquid micro array and enzyme-linked immunosorbent assay. Subsequently, the assay was optimised to detect and titrate anti-p24 IgG3 responses in a panel of sequential specimens from seroconverters over 24 months. The kinetics of p24-specific IgG3 titres revealed a transient peak in the 4 to 5-month period after seroconversion. It was followed by a sharp decline, allowing infections with less than 6 months to be distinguished from older ones. The developed assay exhibited a mean duration of recent infection of 144 days and a false-recent rate of ca. 14%. Our findings show that HIV-1 p24-specific IgG3 titres can be used as a tool to evaluate HIV incidence in serosurveys and to monitor the efficacy of vaccines and other transmission control strategies.
机译:减少人类免疫缺陷病毒1型(HIV-1)传播的风险仍然是公共卫生的重点。有效控制策略的发展取决于对疾病发生率的预防和治疗措施的量化。尽管可以使用几种检测方法来估计HIV发生率,但这些检测方法在区分近期感染和长期感染方面的性能较差,因此受到了这些估计的限制。为了解决这种局限性,我们开发了一种测定方法来滴定p24特异性IgG3抗体作为近期感染的标记。该测定法基于重组p24蛋白,该蛋白能够使用液体微阵列和酶联免疫吸附测定法检测血清中的总IgG抗体。随后,对测定进行了优化,以检测和滴定在24个月内来自血清转化者的一系列连续样本中的抗p24 IgG3反应。 p24特异性IgG3滴度的动力学在血清转化后的4至5个月内显示了一个瞬时峰值。随后急剧下降,可以将少于6个月的感染与较早的感染区分开。发达的检测方法显示最近感染的平均持续时间为144天,错误率大约为。 14%。我们的发现表明,HIV-1 p24特异性IgG3滴度可以用作评估血清调查中HIV发生率并监测疫苗和其他传播控制策略的有效性的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号